Targeting signal transduction with large combinatorial collections

Drug Discovery Today

Volumn 7, Issue 24, 2002, Pages 1206-1213

  Auld, Douglas S ^a   Diller, David ^a   Ho, Koc Kan ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE; LIGAND; MORPHINE; OPIATE; PEPTIDE; SEROTONIN;

COMBINATORIAL CHEMISTRY; DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; DRUG TARGETING; GENOMICS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DELIVERY SYSTEMS; HUMANS; SIGNAL TRANSDUCTION;

EID: 0037114945     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02530-8     Document Type: Review

References (57)

1. Ray L.B., Gough N.R. Orienteering strategies for a signaling maze. Science. 296:2002;1632-1633.
2. Workman P. A gold mine for therapeutic targets. Sebti S.M., Hamilton A.D. Farnesyltransferase Inhibitors in Cancer Therapy: Signal Transduction Pathways. 2001;1-20 Humana Press.
3. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964.
4. Stadel J.M., et al. A high affinity agonist β-adrenergic receptor complex is an intermediate for catecholamine stimulation of adenylate cyclase in turkey and frog erythrocyte membranes. J. Biol. Chem. 255:1980;1436-1441.
5. Samama P., et al. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268:1993;4625-4636.
6. Schwyzer R. Organization and transduction of peptide information. Trends Pharmacol. Sci. 1:1980;327-331.
7. MacDonald R.L., Olsen R.W. GABAA receptor channels. Annu. Rev. Neurosci. 17:1994;569-602.
8. Thorpe D.S. Forecasting roles of combinatorial chemistry in the age of genomically derived drug discovery targets. Comb. Chem. High Throughput Screen. 3:2000;421-436.
9. Fauchere J.L. Discovery and design of peptide and non-peptide ligands to G protein-coupled receptors. NATO Sci. Ser. Ser. A. 307:1999;52-63.
10. Appell K., et al. Combinatorial chemistry and high-throughput screening in drug discovery and development. Handbook of Modern Pharmaceutical Analysis. 2001;23-56 Academic Press.
11. Lange G., et al. Principles governing the binding of a class of non-peptidic inhibitors domain of src studied by X-ray analysis. J. Med. Chem. 45:2002;2915-2922.
12. Al-Obeidi F.A., Lam K.S. Development of inhibitors for protein tyrosine kinases. Oncogene. 19:2000;5690-5701.
13. Dalgarno D.C., et al. Signal transduction drug discovery: targets, mechanisms and structure-based design. Curr. Opin. Drug Discov. Devel. 3:2000;549-564.
14. Spencer R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol. Bioeng. 61:1998;61-67.
15. Sawyers C.L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12:2002;111-115.
16. Shawver L.K., et al. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1:2002;117-123.
17. Hooft van Huijsduijnen R., et al. Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today. 7:2002;1013-1019.
18. Schindler T., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
19. Adams J., Lee D. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinase. Curr. Opin. Drug Discov. Devel. 2:1999;96-109.
20. Dumas J., et al. Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 10:2000;2047-2050.
21. Sarmiento M., et al. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B. J. Med. Chem. 43:2000;146-155.
22. Xue L., et al. A dual fingerprint-based metric for the design of focused compound libraries and analogs. J. Mol. Model. 7:2001;125-131.
23. Ghosh S., et al. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr. Cancer Drug Targets. 1:2001;129-140.
24. Dolle R.E. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem. 3:2001;477-517.
25. Borchardt A., Still W.C. Synthetic receptor binding elucidated with an encoded combinatorial library. J. Am. Chem. Soc. 116:1994;373-374.
26. Baldwin J.J. Design, synthesis and use of binary encoded synthetic chemical libraries. Mol. Divers. 2:1996;81-88.
27. Chabala J.C. Solid-phase combinatorial chemistry and novel tagging methods for identifying leads. Curr. Opin. Biotechnol. 6:1995;632-639.
28. Burbaum J.J., et al. A paradigm for drug discovery employing encoded combinatorial libraries. Proc. Natl. Acad. Sci. U. S. A. 92:1995;6027-6031.
29. McMillan K., et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. U. S. A. 97:2000;1506-1511.
30. Blasko E., et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J. Biol. Chem. 277:2002;295-302.
31. Myers P.L. Will combinatorial chemistry deliver real medicines? Curr. Opin. Biotechnol. 8:1997;701-707.
32. Sarshar S., et al. 2,4,5-Trisubstituted imidazoles novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. part 1. Bioorg. Med. Chem. Lett. 10:2000;2599-2601.
33. Zhang C., et al. 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2. Bioorg. Med. Chem. Lett. 10:2000;2603-2605.
34. Cohen M.H., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8:2002;935-942.
35. La Rosee P., et al. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia. 16:2002;1213-1219.
36. Elices M.J. BX-471(Berlex). Curr. Opin. Invest. Drugs. 3:2002;865-869.
37. Clark D.E., Pickett S.D. Computational methods for the prediction of 'drug-likeness'. Drug Discov. Today. 5:2000;49-57.
38. Muegge I., et al. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 44:2001;1841-1846.
39. Walters W.P., et al. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 3:1999;384-387.
40. Yoshida F., Topliss J.G. QSAR model for drug human oral bioavailability. J. Med. Chem. 43:2000;2575-2585.
41. van de Waterbeemd H., et al. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44:2001;1313-1333.
42. Veber D.F., et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2002;2615-2623.
43. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26.
44. Egan W.J., et al. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43:2000;3867-3877.
45. Ghose A.K., et al. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of ALOGP and CLOGP methods. J. Phys. Chem. A. 102:1998;3762-3772.
46. Teaque S., et al. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. Engl. 38:1999;3743-3748.
47. Hann M.M., et al. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41:2001;856-864.
48. Evans B.E., et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:1988;2235-2246.
49. Patchett A.A., Nargund R.P. Privileged structures - an update. Ann. Report Med. Chem. 35:2000;289-298. Ch. 26.
50. Landro J.A., et al. HTS in the new millennium. The role of pharmacology and flexibility. J. Pharm. Tox. Meth. 44:2000;273-289.
51. Appell K.C., et al. Biological screening of a large combinatorial library. J. Biomol. Screen. 1:1996;27-31.
52. Dolle R.E., et al. A statistical-based approach to assessing the fidelity of combinatorial libraries encoded with electrophoric molecular tags. Development and application of tag decode-assisted single bead LC/MS analysis. J. Comb. Chem. 2:2000;716-731.
53. Hunter J.S. Applying statistics to solving chemical problems. CHEMTECH. 17:1987;167-169.
54. Topliss J.G. Utilization of operational schemes for analog synthesis in drug design. J. Med. Chem. 15:1972;1006-1011.
55. Croston G.E. Functional cell-based uHTS in chemical genomic drug discovery. Trends Biotechnol. 20:2002;110-115.
56. Inglese J. Expanding the HTS paradigm. Drug Discov. Today. 7:(Suppl.):2002;S105-S106.
57. Hobbs D.W., Guo T. Library design concepts and implementation strategies. Ghose A.K., Viswanadhan V.N. Combinatorial Library Design and Evaluation: Principles, Software Tools, and Applications in Drug Discovery. 2001;1-49 Marcel Dekker.